strontium malonate

Strontium malonate is a novel orally available small molecule drug under investigation for the treatment and prevention of osteoporosis, particularly postmenopausal osteoporosis. It is designed to provide skeletal benefits by simultaneously increasing bone formation and decreasing bone resorption. The mechanism of action involves acting as a calcium-sensing receptor agonist, which leads to stimulation of osteoblast activity (bone formation) and inhibition of osteoclast-mediated bone resorption. Strontium malonate has been developed by Osteologix Inc (Osteologix Holdings Plc), with licensing agreements involving Les Laboratoires Servier SAS for markets outside the US. The drug reached Phase 2 clinical trials for postmenopausal osteoporosis[1][2][3][4][5][8].

Other names

strontium malonatestrontium;propanedioate